Key Points
- Srinivas Akkaraju bought 186,377 shares on Dec. 5 at $9.84 and, combining purchases from Nov. 17–Dec. 5, accumulated a total of 989,074 shares (≈$7.62M), raising his stake to 1,265,253 shares—a 17.28% increase.
- Alumis opened at $11.43 (1‑year range $2.76–$11.57) after a quarterly EPS and revenue miss, and analysts hold a consensus "Moderate Buy" rating with an average target of $19.20.
Alumis Inc. (NASDAQ:ALMS - Get Free Report) Director Srinivas Akkaraju acquired 186,377 shares of the business's stock in a transaction on Friday, December 5th. The shares were bought at an average cost of $9.84 per share, with a total value of $1,833,949.68. Following the completion of the acquisition, the director owned 1,265,253 shares of the company's stock, valued at approximately $12,450,089.52. This trade represents a 17.28% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Srinivas Akkaraju also recently made the following trade(s):
- On Thursday, December 4th, Srinivas Akkaraju purchased 66,027 shares of Alumis stock. The stock was purchased at an average price of $8.18 per share, for a total transaction of $540,100.86.
- On Wednesday, December 3rd, Srinivas Akkaraju acquired 100,000 shares of Alumis stock. The shares were purchased at an average cost of $7.75 per share, for a total transaction of $775,000.00.
- On Tuesday, December 2nd, Srinivas Akkaraju acquired 96,000 shares of Alumis stock. The shares were purchased at an average cost of $7.55 per share, with a total value of $724,800.00.
- On Monday, December 1st, Srinivas Akkaraju bought 86,350 shares of Alumis stock. The stock was acquired at an average cost of $7.46 per share, for a total transaction of $644,171.00.
- On Friday, November 28th, Srinivas Akkaraju purchased 38,702 shares of Alumis stock. The shares were acquired at an average cost of $7.64 per share, with a total value of $295,683.28.
- On Wednesday, November 26th, Srinivas Akkaraju acquired 48,537 shares of Alumis stock. The stock was acquired at an average price of $7.64 per share, with a total value of $370,822.68.
- On Thursday, November 20th, Srinivas Akkaraju bought 125,743 shares of Alumis stock. The shares were acquired at an average price of $7.20 per share, for a total transaction of $905,349.60.
- On Wednesday, November 19th, Srinivas Akkaraju purchased 137,772 shares of Alumis stock. The stock was acquired at an average cost of $6.56 per share, with a total value of $903,784.32.
- On Tuesday, November 18th, Srinivas Akkaraju acquired 102,652 shares of Alumis stock. The shares were bought at an average cost of $6.05 per share, for a total transaction of $621,044.60.
- On Monday, November 17th, Srinivas Akkaraju acquired 914 shares of Alumis stock. The stock was bought at an average price of $5.51 per share, with a total value of $5,036.14.
Alumis Trading Up 2.4%
Shares of NASDAQ ALMS opened at $11.43 on Wednesday. Alumis Inc. has a 1-year low of $2.76 and a 1-year high of $11.57. The company has a 50-day moving average of $5.77 and a two-hundred day moving average of $4.56. The company has a market cap of $1.19 billion, a PE ratio of -2.82 and a beta of -1.91.
Alumis (NASDAQ:ALMS - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The company had revenue of $2.07 million for the quarter, compared to analysts' expectations of $3.14 million. As a group, equities research analysts forecast that Alumis Inc. will post -8.51 earnings per share for the current year.
Institutional Investors Weigh In On Alumis
Several hedge funds have recently bought and sold shares of the company. Samsara Biocapital LLC increased its position in shares of Alumis by 47.0% in the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company's stock valued at $14,404,000 after buying an additional 1,534,872 shares in the last quarter. Foresite Capital Management VI LLC increased its holdings in shares of Alumis by 1.1% in the second quarter. Foresite Capital Management VI LLC now owns 4,247,670 shares of the company's stock worth $12,743,000 after acquiring an additional 45,000 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Alumis by 18.4% during the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company's stock worth $16,078,000 after purchasing an additional 625,404 shares during the period. Trium Capital LLP lifted its holdings in shares of Alumis by 17.9% during the 3rd quarter. Trium Capital LLP now owns 3,122,111 shares of the company's stock valued at $12,457,000 after purchasing an additional 474,072 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new position in shares of Alumis in the 2nd quarter valued at approximately $5,779,000.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on ALMS shares. Wall Street Zen upgraded Alumis from a "sell" rating to a "hold" rating in a research report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alumis in a research report on Monday. HC Wainwright reissued a "buy" rating and set a $14.00 price target on shares of Alumis in a research note on Thursday, August 14th. Finally, Morgan Stanley reduced their price objective on shares of Alumis from $23.00 to $22.00 and set an "overweight" rating on the stock in a research note on Friday, August 15th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $19.20.
View Our Latest Analysis on Alumis
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
